Franck E. Nicolini, Anna Turkina, Zhi-Xiang Shen, Neil Gallagher, Saengsuree Jootar, Bayard L. Powell, Carmino De Souza, Ming Zheng, Tomasz Szczudlo and Philipp le Coutre Expanding Nilotinib Access in Clinical Trials (ENACT) Cancer 118
Version of Record online: 5 JUL 2011 | DOI: 10.1002/cncr.26249
ENACT is the largest clinical study of patients with chronic myeloid leukemia in the chronic phase (N = 1422) who failed prior imatinib therapy because of resistance or intolerance. This study confirms the clinical efficacy and safety of nilotinib for the treatment of these patients, which was observed in the phase 2 registration study.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field